在线客服

晓洁:

198-8659-7060

MCF-7人乳腺癌细胞[STR鉴定正确]

产品型号:BH-C012
产品规格:1×10^6cell/T25瓶
产品价格:¥1320

返回列表

商品详情相关试剂说明书下载参考文献

商品详情

目录号

BH-C012

细胞英文(简称)

MCF7 [MCF-7]

细胞名称

MCF7 [MCF-7]人乳腺癌细胞【已通过STR鉴定】

背景资料

MCF-7细胞保留了多个分化了的乳腺上皮的特性,包括:能通过胞质雌激素受体加工雌二醇并能形成圆形复合物(domes)。该细胞含有Tx-4癌基因。肿瘤坏死因子αTNF alpha)可以抑制MCF-7细胞的生长。抗雌激素处理细胞能调变IGFBP’S的分泌。

细胞来源

ATCC HTB-22

代次

P3

规格

冻存管/培养瓶

细胞数

1x10^6 cells

生物安全级别

2

组织来源

腺癌,乳腺,胸水

细胞形态

贴壁;上皮细胞样

细胞活力

95%(Viability by Trypan Blue Exclusion

细胞检测

细胞不含有HIV-1HBVHCV、支原体、细菌、酵母和真菌

培养条件

DMEM(高糖)+10% FBS(货号:C2056-1A+1%P/S37℃5% CO2

传代方法

建议1:2-1:3 两天换液一次

冻存条件

无血清细胞冻存液(货号:S002

参考文献

PubMed=4357757; DOI=10.1093/jnci/51.5.1409
Soule H.D., Vazguez J., Long A., Albert S., Brennan M.
A human cell line from a pleural effusion derived from a breast carcinoma.
J. Natl. Cancer Inst. 51:1409-1416(1973)

PubMed=4138511; DOI=10.1038/252247a0
McGrath C.M., Grant P.M., Soule H.D., Glancy T., Rich M.A.
Replication of oncornavirus-like particle in human breast carcinoma cell line, MCF-7.
Nature 252:247-250(1974)

PubMed=1000504
Lippman M.E., Bolan G., Huff K.
The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture.
Cancer Res. 36:4595-4601(1976)

PubMed=1000505
Lippman M.E., Bolan G., Huff K.
The effects of glucocorticoids and progesterone on hormone-responsive human breast cancer in long-term tissue culture.
Cancer Res. 36:4602-4609(1976)

PubMed=1000506
Lippman M.E., Bolan G., Huff K.
The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture.
Cancer Res. 36:4610-4618(1976)

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=7228867; DOI=10.1016/S0021-9258(19)69359-2
Nawata H., Bronzert D.A., Lippman M.E.
Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast cancer cells.
J. Biol. Chem. 256:5016-5021(1981)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3702420; DOI=10.1016/0022-4731(86)90083-X
Devleeschouwer N., Olea-Serrano N., Leclercq G., Legros N., Heuson J.C.
Induction of progesterone receptor in an estrogen, progesterone receptor-negative breast cancer cell line.
J. Steroid Biochem. 24:365-368(1986)

PubMed=3335022
Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)

PubMed=1911442; DOI=10.1016/0960-0760(91)90248-4
Wild M.J., Rudland P.S., Back D.J.
Metabolism of the oral contraceptive steroids ethynylestradiol and norgestimate by normal (Huma 7) and malignant (MCF-7 and ZR-75-1) human breast cells in culture.
J. Steroid Biochem. Mol. Biol. 39:535-543(1991)

DOI=10.1016/B978-0-12-333530-2.50009-5
Leibovitz A.
Cell lines from human breast.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York (1994)

PubMed=7531416
Rostagno P., Moll J.-L., Birtwisle-Peyrottes I., Ettore F., Lagrange J.-L., Gioanni J., Caldani C.
Effects of tamoxifen on potential doubling time of human breast cancer cell line determined by image cytometry of double fluorescent BrdU and DNA labeling.
Anticancer Res. 14:2025-2032(1994)

PubMed=7842014; DOI=10.1038/ng1094-155
Guan X.-Y., Meltzer P.S., Dalton W.S., Trent J.M.
Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection.
Nat. Genet. 8:155-161(1994)

PubMed=7498097; DOI=10.1289/ehp.95103844
Villalobos M., Olea N., Brotons J.A., Olea-Serrano M.F., Ruiz de Almodovar J.M., Pedraza V.
The E-screen assay: a comparison of different MCF7 cell stocks.
Environ. Health Perspect. 103:844-850(1995)

PubMed=8626706; DOI=10.1074/jbc.271.19.11477
Quinn K.A., Treston A.M., Unsworth E.J., Miller M.-J., Vos M., Grimley C., Battey J., Mulshine J.L., Cuttitta F.
Insulin-like growth factor expression in human cancer cell lines.
J. Biol. Chem. 271:11477-11483(1996)

PubMed=8824553; DOI=10.1002/(SICI)1097-0215(19960917)67:6<816::aid-ijc10>3.0.CO;2-#
Mullen P., Ritchie A., Langdon S.P., Miller W.R.
Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines.
Int. J. Cancer 67:816-820(1996)

PubMed=9242427
Levenson A.S., Jordan V.C.
MCF-7: the first hormone-responsive breast cancer cell line.
Cancer Res. 57:3071-3078(1997)

PubMed=9671407; DOI=10.1038/sj.onc.1201814
Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
Oncogene 16:2865-2878(1998)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V., Jeffrey S.S., van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=10862037; DOI=10.1002/1098-2264(200007)28:3<308::aid-gcc9>3.0.CO;2-B
Kytola S., Rummukainen J., Nordgren A., Karhu R., Farnebo F., Isola J., Larsson C.
Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping.
Genes Chromosomes Cancer 28:308-317(2000)

PubMed=10969801
Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y., Gooden G.C., Ethier S.P., Kallioniemi A., Kallioniemi O.-P.
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
Cancer Res. 60:4519-4525(2000)

PubMed=11044355; DOI=10.1054/bjoc.2000.1458
Davidson J.M., Gorringe K.L., Chin S.-F., Orsetti B., Besret C., Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.
Molecular cytogenetic analysis of breast cancer cell lines.
Br. J. Cancer 83:1309-1317(2000)

PubMed=11078910; DOI=10.1016/S0304-3835(00)00579-6
Lilling G., Hacohen H., Nordenberg J., Livnat T., Rotter V., Sidi Y.
Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: possible relation to high bcl-2/bax ratio?
Cancer Lett. 161:27-34(2000)

PubMed=11292682; DOI=10.1096/fj.00-0527fje
Vassy J., Portet S., Beil M., Millot G., Fauvel-Lafeve F., Karniguian A., Gasset G., Irinopoulou T., Calvo F., Rigaut J.P., Schoevaert D.
The effect of weightlessness on cytoskeleton architecture and proliferation of human breast cancer cell line MCF-7.
FASEB J. 15:1104-1106(2001)

PubMed=11789735; DOI=10.1309/4NCM-QJ9W-QM0J-6QJE
Rhodes A., Jasani B., Couturier J., McKinley M.J., Morgan J.M., Dodson A.R., Navabi H., Miller K.D., Balaton A.J.
A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer.
Am. J. Clin. Pathol. 117:81-89(2002)

PubMed=12353263; DOI=10.1002/gcc.10107
Popovici C., Basset C., Bertucci F., Orsetti B., Adelaide J., Mozziconacci M.-J., Conte N., Murati A., Ginestier C., Charafe-Jauffret E., Ethier S.P., Lafage-Pochitaloff M., Theillet C., Birnbaum D., Chaffanet M.
Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.
Genes Chromosomes Cancer 35:204-218(2002)

PubMed=12661003; DOI=10.1002/gcc.10196
Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.-F., Schlag P.M., Scherneck S.
Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.
Genes Chromosomes Cancer 37:29-35(2003)

PubMed=12775708; DOI=10.1074/jbc.M305226200
Martin L.-A., Farmer I., Johnston S.R.D., Ali S., Marshall C., Dowsett M.
Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation.
J. Biol. Chem. 278:30458-30468(2003)

PubMed=12800145; DOI=10.1002/gcc.10218
Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Genes Chromosomes Cancer 37:333-345(2003)

PubMed=15002416; DOI=10.1016/S0273-1177(03)90400-5
Vassy J., Portet S., Beil M., Millot G., Fauvel-Lafeve F., Gasset G., Schoevaert D.
Weightlessness acts on human breast cancer cell line MCF-7.
Adv. Space Res. 32:1595-1603(2003)

PubMed=15361840; DOI=10.1038/sj.onc.1207966
Usary J., Llaca V., Karaca G., Presswala S., Karaca M., He X.-P., Langerod A., Karesen R., Oh D.S., Dressler L.G., Lonning P.E., Strausberg R.L., Chanock S.J., Borresen-Dale A.-L., Perou C.M.
Mutation of GATA3 in human breast tumors.
Oncogene 23:7669-7678(2004)

PubMed=15677628; DOI=10.1093/carcin/bgi032
Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Carcinogenesis 26:923-930(2005)

PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11.1-11.8(2005)

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234
Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Mol. Cancer Ther. 4:399-412(2005)

PubMed=15900046; DOI=10.1093/jnci/dji133
Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.
p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.
J. Natl. Cancer Inst. 97:765-777(2005)

PubMed=16142302; DOI=10.3892/ijo.27.4.881
de Longueville F., Lacroix M., Barbuto A.-M., Bertholet V., Gallo D., Larsimont D., Marcq L., Zammatteo N., Boffe S., Leclercq G., Remacle J.
Molecular characterization of breast cancer cell lines by a low-density microarray.
Int. J. Oncol. 27:881-892(2005)

PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 66:41-45(2006)

PubMed=16541312; DOI=10.1007/s10549-006-9186-z
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Breast Cancer Res. Treat. 99:97-101(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008
Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10:515-527(2006)

PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001
Azari S., Ahmadi N., Tehrani M.J., Shokri F.
Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.
Biologicals 35:195-202(2007)

PubMed=18516279; DOI=10.1016/j.molonc.2007.02.004
Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R., Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H., Petersen O.W., Gray J.W., Bissell M.J.
The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.
Mol. Oncol. 1:84-96(2007)

PubMed=18386134; DOI=10.1007/s10585-008-9169-z
Hughes L., Malone C., Chumsri S., Burger A.M., McDonnell S.
Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity.
Clin. Exp. Metastasis 25:549-557(2008)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=19582160; DOI=10.1371/journal.pone.0006146
Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R.
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
PLoS ONE 4:E6146-E6146(2009)

PubMed=19727395; DOI=10.1371/journal.pone.0006888
Wadlow R.C., Wittner B.S., Finley S.A., Bergquist H., Upadhyay R., Finn S.P., Loda M., Mahmood U., Ramaswamy S.
Systems-level modeling of cancer-fibroblast interaction.
PLoS ONE 4:E6888-E6888(2009)

CLPUB00423
Morrison B.J.
Breast cancer stem cells: tumourspheres and implications for therapy.
Thesis PhD (2010), Griffith University, Australia

PubMed=19593635; DOI=10.1007/s10549-009-0460-8
Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F., Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J., Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M., Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M., Dinjens W.N.M., Ethier S.P., Clevers H., Jochemsen A.G., den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
Breast Cancer Res. Treat. 121:53-64(2010)

PubMed=20070913; DOI=10.1186/1471-2407-10-15
Tsuji K., Kawauchi S., Saito S., Furuya T., Ikemoto K., Nakao M., Yamamoto S., Oka M., Hirano T., Sasaki K.
Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.
BMC Cancer 10:15.1-15.10(2010)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

DOI=10.4172/2157-7145.S2-005
Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M., Hart R.P., Furtado M.R.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
J. Forensic Res. 2 Suppl. 2:5-5(2011)

PubMed=21247443; DOI=10.1186/gb-2011-12-1-r6
Edgren H., Murumagi A., Kangaspeska S., Nicorici D., Hongisto V., Kleivi K., Rye I.H., Nyberg S., Wolf M., Borresen-Dale A.-L., Kallioniemi O.-P.
Identification of fusion genes in breast cancer by paired-end RNA-sequencing.
Genome Biol. 12:R6.1-R6.13(2011)

PubMed=21378333
Ford C.H.J., Al-Bader M., Al-Ayadhi B., Francis I.
Reassessment of estrogen receptor expression in human breast cancer cell lines.
Anticancer Res. 31:521-527(2011)

PubMed=22068913; DOI=10.1073/pnas.1111840108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=22278370; DOI=10.1074/mcp.M111.014050
Geiger T., Wehner A., Schaab C., Cox J., Mann M.
Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins.
Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017
Kong D., Yamori T.
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22414580; DOI=10.1158/0008-5472.CAN-11-3711
Geiger T., Madden S.F., Gallagher W.M., Cox J., Mann M.
Proteomic portrait of human breast cancer progression identifies novel prognostic markers.
Cancer Res. 72:2428-2439(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224
Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Cancer Discov. 2:172-189(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23285151; DOI=10.1371/journal.pone.0052692
Morrison B.J., Hastie M.L., Grewal Y.S., Bruce Z.C., Schmidt C., Reynolds B.A., Gorman J.J., Lopez J.A.
Proteomic comparison of MCF-7 tumoursphere and monolayer cultures.
PLoS ONE 7:E52692-E52692(2012)

CLPUB00336
Crane A., Brennan M., Naebers R.
Catherine Frances Mallon's 'immortal cells'.
IHM Arch. Notes 4:2.1-2.1(2013)

PubMed=23234512; DOI=10.1021/pr300898u
Segura V., Medina-Aunon J.A., Guruceaga E., Gharbi S.I., Gonzalez-Tejedo C., Sanchez del Pino M.M., Canals F., Fuentes M., Casal J.I., Martinez-Bartolome S., Elortza F., Mato J.M., Arizmendi J.M., Abian J., Oliveira E., Gil C., Vivanco F., Blanco F., Albar J.P., Corrales F.J.
Spanish human proteome project: dissection of chromosome 16.
J. Proteome Res. 12:112-122(2013)

PubMed=23325432; DOI=10.1101/gr.147942.112
Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E., Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A., Crawford G.E., Absher D.M., Wold B.J., Myers R.M.
Dynamic DNA methylation across diverse human cell lines and tissues.
Genome Res. 23:555-567(2013)

PubMed=23601657; DOI=10.1186/bcr3415
Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A., Martens J.W.M.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res. 15:R33.1-R33.17(2013)

PubMed=23671654; DOI=10.1371/journal.pone.0063056
Lu Y.-H., Soong T.D., Elemento O.
A novel approach for characterizing microsatellite instability in cancer cells.
PLoS ONE 8:E63056-E63056(2013)

PubMed=23770244; DOI=10.1016/j.celrep.2013.05.024
Wierer M., Verde G., Pisano P., Molina H., Font-Mateu J., Di Croce L., Beato M.
PLK1 signaling in breast cancer cells cooperates with estrogen receptor-dependent gene transcription.
Cell Rep. 3:2021-2032(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23868472; DOI=10.1038/ncomms3175
Johansson H.J., Sanchez B.C., Mundt F., Forshed J., Kovacs A., Panizza E., Hultin-Rosenberg L., Lundgren B., Martens U., Mathe G., Yakhini Z., Helou K., Krawiec K., Kanter L., Hjerpe A., Stal O., Linderholm B.K., Lehtio J.
Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer.
Nat. Commun. 4:2175.1-2175.10(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24009699; DOI=10.1371/journal.pone.0072704
Liu X., Nie H., Zhang Y.-B., Yao Y.-F., Maitikabili A., Qu Y.-P., Shi S.-L., Chen C.-Y., Li Y.
Cell surface-specific N-glycan profiling in breast cancer.
PLoS ONE 8:E72704-E72704(2013)

PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020
Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A., Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K., McCormick F., Gray J.W.
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
Cancer Cell 24:450-465(2013)

PubMed=24162158; DOI=10.1007/s10549-013-2743-3
Prat A., Karginova O., Parker J.S., Fan C., He X., Bixby L., Harrell J.C., Roman E., Adamo B., Troester M., Perou C.M.
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Breast Cancer Res. Treat. 142:237-255(2013)

PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J., Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20.1-20.13(2013)

PubMed=24389870; DOI=10.1038/srep03576
Strauch M., Ludke A., Munch D., Laudes T., Galizia C.G., Martinelli E., Lavra L., Paolesse R., Ulivieri A., Catini A., Capuano R., Di Natale C.
More than apples and oranges -- detecting cancer with a fruit fly's antenna.
Sci. Rep. 4:3576-3576(2014)

PubMed=24618588; DOI=10.1371/journal.pone.0091433
Chernobrovkin A.L., Zubarev R.A.
Detection of viral proteins in human cells lines by xeno-proteomics: elimination of the last valid excuse for not testing every cellular proteome dataset for viral proteins.
PLoS ONE 9:E91433-E91433(2014)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=25321415; DOI=10.1210/me.2014-1229
Li Y., Arao Y., Hall J.M., Burkett S., Liu L.-W., Gerrish K., Cavailles V., Korach K.S.
Research resource: STR DNA profile and gene expression comparisons of human BG-1 cells and a BG-1/MCF-7 clonal variant.
Mol. Endocrinol. 28:2072-2081(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25807930; DOI=10.1002/anie.201500342
Broncel M., Serwa R.A., Ciepla P., Krause E., Dallman M.J., Magee A.I., Tate E.W.
Multifunctional reagents for quantitative proteome-wide analysis of protein modification in human cells and dynamic profiling of protein lipidation during vertebrate development.
Angew. Chem. Int. Ed. 54:5948-5951(2015)

PubMed=25828948; DOI=10.1093/jnci/djv073
Lee A.V., Oesterreich S., Davidson N.E.
MCF-7 cells -- changing the course of breast cancer research and care for 45 years.
J. Natl. Cancer Inst. 107:djv073.1-djv073.4(2015)

PubMed=26026074
Comsa S., Cimpean A.M., Raica M.
The story of MCF-7 breast cancer cell line: 40 years of experience in research.
Anticancer Res. 35:3147-3154(2015)

PubMed=26055192; DOI=10.1021/acs.jproteome.5b00375
Cifani P., Kirik U., Waldemarson S., James P.
Molecular portrait of breast-cancer-derived cell lines reveals poor similarity with tumors.
J. Proteome Res. 14:2819-2827(2015)

PubMed=26116361; DOI=10.1158/1535-7163.MCT-15-0143
Ribas R., Pancholi S., Guest S.K., Marangoni E., Gao Q., Thuleau A., Simigdala N., Polanska U.M., Campbell H., Rani A., Liccardi G., Johnston S.R.D., Davies B.R., Dowsett M., Martin L.-A.
AKT antagonist AZD5363 influences estrogen receptor function in endocrine-resistant breast cancer and synergizes with fulvestrant (ICI182780) in vivo.
Mol. Cancer Ther. 14:2035-2048(2015)

PubMed=26330541; DOI=10.1074/mcp.M115.050484
Wu X., Zahari M.S., Renuse S., Nirujogi R.S., Kim M.-S., Manda S.S., Stearns V., Gabrielson E.W., Sukumar S., Pandey A.
Phosphoproteomic analysis identifies focal adhesion kinase 2 (FAK2) as a potential therapeutic target for tamoxifen resistance in breast cancer.
Mol. Cell. Proteomics 14:2887-2900(2015)

PubMed=27331101; DOI=10.1016/j.dib.2016.05.040
Aumsuwan P., Khan S.I., Khan I.A., Walker L.A., Dasmahapatra A.K.
Gene expression profiling and pathway analysis data in MCF-7 and MDA-MB-231 human breast cancer cell lines treated with dioscin.
Data Brief 8:272-279(2016)

PubMed=27362937; DOI=10.1371/journal.pone.0157290
Carrier M., Joint M., Lutzing R., Page A., Rochette-Egly C.
Phosphoproteome and transcriptome of RA-responsive and RA-resistant breast cancer cell lines.
PLoS ONE 11:E0157290-E0157290(2016)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27378269; DOI=10.1186/s12885-016-2452-5
Kangaspeska S., Hultsch S., Jaiswal A., Edgren H., Mpindi J.P., Eldfors S., Bruck O., Aittokallio T., Kallioniemi O.-P.
Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.
BMC Cancer 16:378.1-378.17(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27456714; DOI=10.1038/srep28994
Kleensang A., Vantangoli M.M., Odwin-DaCosta S., Andersen M.E., Boekelheide K., Bouhifd M., Fornace A.J. Jr., Li H.-H., Livi C.B., Madnick S., Maertens A., Rosenberg M., Yager J.D., Zhaog L., Hartung T.
Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function.
Sci. Rep. 6:28994-28994(2016)

PubMed=27761513; DOI=10.1016/j.dib.2016.09.025
Sarvaiya H.A., Lazar I.M.
Insulin stimulated MCF7 breast cancer cells: proteome dataset.
Data Brief 9:579-584(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20.1-20.11(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470
Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.
Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile.
J. Proteome Res. 16:1391-1400(2017)

PubMed=28601559; DOI=10.1016/j.cels.2017.05.009
Bekker-Jensen D.B., Kelstrup C.D., Batth T.S., Larsen S.C., Haldrup C., Bramsen J.B., Sorensen K.D., Hoyer S., Orntoft T.F., Andersen C.L., Nielsen M.L., Olsen J.V.
An optimized shotgun strategy for the rapid generation of comprehensive human proteomes.
Cell Syst. 4:587-599.e4(2017)

PubMed=28889351; DOI=10.1007/s10549-017-4496-x
Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L., Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E., Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J., Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E., Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F., Lakhani S.R.
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
Breast Cancer Res. Treat. 167:289-301(2018)

PubMed=29273624; DOI=10.1101/gr.226019.117
Franco H.L., Nagari A., Malladi V.S., Li W.-Q., Xi Y.-X., Richardson D., Allton K.L., Tanaka K., Li J., Murakami S., Keyomarsi K., Bedford M.T., Shi X.-B., Li W., Barton M.C., Dent S.Y.R., Kraus W.L.
Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis.
Genome Res. 28:159-170(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=34320349; DOI=10.1016/j.celrep.2021.109441
Jochems F., Thijssen B., De Conti G., Jansen R., Pogacar Z., Groot K., Wang L.-Q., Schepers A., Wang C., Jin H.-J., Beijersbergen R.L., Leite de Oliveira R., Wessels L.F.A., Bernards R.
The cancer SENESCopedia: a delineation of cancer cell senescence.
Cell Rep. 36:109441-109441(2021)

联系我们
  • 19886597060